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Casitas B-lineage lymphoma-b (Cbl-b) is an E3 ubiquitin ligase that negatively regulates 
T cell activation. Cbl-b−/− T cells are hyper-reactive and co-stimulation independent, and 
Cbl-b−/− mice demonstrate robust T cell and NK cell-mediated antitumor immunity. As a 
result of these murine studies, Cbl-b is considered a potential target for therapeutic 
manipulation in human cancer immunotherapy. The PD-L1/PD-1 pathway of immune 
regulation is presently an important therapeutic focus in tumor immunotherapy, and 
although Cbl-b−/− mice have been shown to be resistant to several immuno-regulatory 
mechanisms, the sensitivity of Cbl-b−/− mice to PD-L1-mediated suppression has not 
been reported. We now document that Cbl-b−/− T cells and NK cells are resistant to 
PD-L1/PD-1-mediated suppression. Using a PD-L1 fusion protein (PD-L1 Ig), this 
resistance is shown for both in vitro proliferative responses and IFN-γ production and is 
not associated with decreased PD-1 expression on Cbl-b−/− cells. In coculture studies, 
Cbl-b−/− CD8+, but not CD4+ T cells, diminish the PD-L1 Ig-mediated suppression of 
bystander naïve WT CD8+ T cells. Using an in vivo model of B16 melanoma in which 
numerous liver metastases develop in WT mice in a PD-1 dependent manner, Cbl-b−/− 
mice develop significantly fewer liver metastases without the administration of anti-PD-1 
antibody. Overall, our findings identify a new mode of immuno-regulatory resistance 
associated with Cbl-b deficiency and suggest that resistance to PD-L1/PD-1-mediated 
suppression is a novel mechanism by which Cbl-b deficiency leads to enhanced 
antitumor immunity. Our results suggest that targeting Cbl-b in cancer immunotherapy 
offers the opportunity to simultaneously override numerous relevant “checkpoints,” 
including sensitivity to regulatory T cells, suppression by TGF-β, and immune regulation 
by both CTLA-4 and, as we now report, by the PD-L1/PD-1 pathway.
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inTrODUcTiOn
Casitas B-lineage lymphoma-b (Cbl-b) is an E3 ubiquitin ligase that regulates many aspects of 
cell activation. Cbl-b functions in T cells to regulate the activation of several proximal T cell 
receptor signaling molecules, including PI3K (1–4). Cbl-b deficiency in mice (Cbl-b−/− mice) 
leads to spontaneous autoimmunity characterized by multi-organ cellular infiltration (1) as well 
Abbreviations: Cbl-b, casitas B-lineage lymphoma-b; PD-L1/PD-1, programmed death-ligand 1/programmed death-1; Tregs, 
regulatory T cells; MFI, mean fluorescence intensity; SHP-1/2, Src homology region 2 domain-containing phosphatase-1/2.
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as increased susceptibility to induced models of autoimmunity 
such as experimental autoimmune encephalomyelitis (2, 5, 6). 
T cells from Cbl-b−/− mice demonstrate hyper-reactivity (1) 
and co-stimulation independence (2). Moreover, we and others 
have shown that Cbl-b−/− T cells are resistant to suppression 
by Tregs (7–9) and TGF-β (7, 10, 11). The potential relevance 
of alterations in Cbl-b in autoimmunity is also supported by 
the finding that single nucleotide polymorphisms in the CBLB 
gene are associated with human autoimmune diseases such 
as systemic lupus erythematosus (12) and multiple sclerosis 
(13). More recently, Cbl-b−/− mice have also become a focus 
for the study of T cell-mediated antitumor immunity, and our 
laboratory and others have reported that Cbl-b−/− mice are 
resistant to the outgrowth of spontaneous and transplantable 
tumors (9–11). In addition to T cell-mediated effects, it has 
recently been reported that Cbl-b−/− mice have enhanced NK 
cell-mediated tumor immunity (14). As a result of these studies, 
Cbl-b is considered a target for therapeutic manipulation in 
cancer immunotherapy.
The PD-L1/PD-1 pathway is recognized as an important 
mechanism of immune regulation in mice and humans (15, 16). 
Moreover, targeting this pathway for inhibition has generated 
much interest as a novel therapeutic approach for enhancing 
tumor immunity in certain human malignancies (17–19). A 
number of mechanisms have been proposed for the normal 
PD-L1/PD-1-mediated regulation of T cells (20–22), and this 
includes the upregulation of Cbl-b in T cells in response to 
PD-L1/PD-1 signaling (23). This upregulation of Cbl-b is postu-
lated to be required for TCR down-modulation and subsequent 
inhibition of T cell activation by PD-L1/PD-1 signaling (23). 
While these studies suggest the potential involvement of Cbl-b 
in the normal PD-L1/PD-1 inhibition of T cell responses, 
this has not been directly examined in the context of Cbl-b 
deficiency.
In the present study, we analyzed PD-L1/PD-1-mediated 
immune regulation utilizing Cbl-b−/− mice. We document for the 
first time that Cbl-b deficiency in mice results in functional resist-
ance of T cells and NK cells to PD-L1/PD-1-mediated regulation. 
Our results thus add to Cbl-b’s role in immune regulation and 




Female C57BL/6 (WT) mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME, USA). Cbl-b−/− mice on a C57BL/6 
background were a gift from Dr. H. Gu (Columbia University, 
New York, NY, USA). Female C57BL/6 congenic mice (CD45.1+) 
were also purchased from the Jackson Laboratory. All mice were 
maintained and bred under specific pathogen-free conditions in 
accordance with the guidelines of the UConn Health Institutional 
Animal Care and Use Committee (IACUC) and the Center for 
Comparative Medicine at UConn Health. The UConn Health 
IACUC has approved the protocol (protocol 101448-0919) used 
in these studies.
In Vitro suppression of T cell Proliferation 
with the recombinant PD-l1 Fusion 
Protein (PD-l1 ig)
Splenic naïve CD8+ CD44low cells isolated via positive selection by 
magnetic bead purification (Miltenyi Biotec, Auburn, CA, USA) 
from WT and Cbl-b−/− mice were labeled with 2.5  µM CFSE 
(Molecular Probe, Eugene, OR, USA) and stimulated with 2 µg/
ml of plate-bound anti-CD3 ab and 0.4  µg/ml of soluble anti-
CD28 ab in the presence of 9–10 µg/ml of plate-bound control Ig 
or PD-L1 Ig for 72 h in 10% FCS complete RPMI 1640 in round-
bottom 96-wells at 5 × 105 cells/ml.
Splenic naive CD4+ CD44low cells isolated via negative selec-
tion by magnetic bead purification (Miltenyi Biotec) from WT 
and Cbl-b−/− mice were labeled with CFSE and stimulated with 
2.5 µg/ml of plate-bound anti-CD3 ab, 1 µg/ml of soluble anti-
CD28 ab in the presence of 10 µg/ml of plate-bound control Ig, 
or PD-L1 Ig for 48 h in 10% FCS complete RPMI 1640 in round-
bottom 96-wells at 2.5 × 105 cells/ml. These cells in both cultures 
were stained with Live/Dead Near IR (Live/Dead) (Molecular 
Probe), anti-CD8α, or anti-CD4 (Biolegend) and analyzed by 
flow cytometry using Becton Dickinson LSRII for CFSE dilution. 
Absolute numbers of cells in these cultures were quantified using 
MACSQuant Analyzer 10 (Miltenyi Biotec). For PD-1 expression, 
unstimulated splenocytes from WT and Cbl-b−/− mice and CD8+ 
or CD4+ T cells stimulated in above conditions without Igs were 
surface-stained with Live/Dead, anti-CD8α or anti-CD4, anti-
CD44, and anti-PD-1 (Biolegend) and analyzed by flow cytometry.
In Vitro suppression of T cell iFn-γ 
Production by the recombinant PD-l1 ig
Splenic naïve CD8+ CD44low T cells isolated via negative selec-
tion by magnetic bead purification (Miltenyi Biotec) from WT 
and Cbl-b−/− mice were stimulated with 2 µg/ml of plate-bound 
anti-CD3 ab and 0.4 µg/ml of soluble anti-CD28 ab in the pres-
ence of 9–10  µg/ml of plate-bound control Ig or PD-L1 Ig for 
72 h in 10% FCS complete RPMI 1640 in round-bottom 96-wells 
at 5 × 105 cells/ml. Splenic naïve CD4+ CD44low T cells isolated 
via negative selection by magnetic bead purification (Miltenyi 
Biotec) from WT and Cbl-b−/− mice were stimulated with 2.5 µg/
ml of plate-bound anti-CD3 ab and 1 µg/ml of soluble anti-CD28 
ab in the presence of 10  µg/ml of plate-bound control Ig or 
PD-L1 Ig for 72 h in 10% FCS complete RPMI 1640 in round-
bottom 96-wells at 2.5 ×  105  cells/ml. CD4+ T cells were then 
re-stimulated overnight with 2.5 µg/ml of plate-bound anti-CD3 
ab and 1 µg/ml of soluble anti-CD28 ab without any Igs. Brefeldin 
A (5 µg/ml) (Sigma-Aldrich, St. Louis, MO, USA) was added to 
both cultures in the last 4 h. Cells were surface-stained with Live/
Dead, anti-CD8α or anti-CD4 then fixed and permeabilized 
using BD Cytoperm/Cytofix kit (BD Biosciences, San Jose, CA, 
USA), intracellularly stained with anti-IFN-γ (BD Biosciences), 
and analyzed by flow cytometry.
In Vitro suppression of nK cell iFn-γ 
Production by the recombinant PD-l1 ig
Splenic NK cells isolated via negative selection by magnetic bead 
purification (STEMCELL Technologies, Vancouver, BC, Canada) 
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from WT and Cbl-b−/− mice were cultured for 7 days in the pres-
ence of 1,000 U/ml recombinant human IL-2 (National Institutes 
of Health, Bethesda, MD) in 10% FCS complete RPMI 1640 
(supplemented with 50  µM 2-mercaptoethanol, l-glutamine, 
penicillin/streptomycin, non-essential amino acids, and sodium 
pyruvate) in 24-wells at 2.5 × 105 cells/ml. The purity of NK cells 
on day 7 was determined by surface-staining with Live/Dead, 
anti-CD3, anti-NK1.1, and anti-CD49b (eBioscience, San Diego, 
CA, USA) by flow cytometry, and the cell number per well for 
the stimulation was normalized based on the NK cell purity 
(CD3− NK1.1+ CD49b+). These NK cells were stimulated with 
15–20  µg/ml of plate-bound anti-NK1.1 ab (Biolegend) in the 
presence of 12.5–15 µg/ml of plate-bound control Ig or PD-L1 
Ig and 5 µg/ml Brefeldin A for 5 h in round-bottom 96-wells at 
5 × 105 cells/ml. These stimulated NK cells and unstimulated NK 
cells (from 7-day IL-2 culture) were surface-stained with Live/
Dead, fixed, and permeabilized as described above and intracel-
lularly stained with anti-IFN-γ or anti-PD-1, and then analyzed 
by flow cytometry.
coculture of WT and cbl-b−/− T cells
Splenic naïve CD8+ CD44low T cells isolated via negative selec-
tion by magnetic bead purification (Miltenyi Biotec) from WT 
congenic mice (CD45.1+) and Cbl-b−/− mice were labeled with 
CFSE and stimulated with 2 µg/ml of plate-bound anti-CD3 ab, 
0.4 µg/ml of soluble anti-CD28 ab in the presence of 9 µg/ml of 
plate-bound control Ig or PD-L1 Ig for 72 h in 10% FCS complete 
RPMI 1640 in round-bottom 96-well plates at 5 × 105 cells/ml. 
Single cultures were set up in which WT congenic naïve CD8+ 
T cells and Cbl-b−/− CD8+ T cells were stimulated separately. 
Cocultures were set up in which these two naïve CD8+ T cell 
populations were cultured and stimulated together. Splenic 
naïve CD4+ CD44low T cells isolated via negative selection 
by magnetic bead purification (Miltenyi Biotec) from WT 
congenic mice and Cbl-b−/− mice were labeled with CFSE and 
stimulated with 2.5 µg/ml of plate-bound anti-CD3 ab, 1 µg/ml 
of soluble anti-CD28 ab in the presence of 15 µg/ml of plate-
bound control Ig, or PD-L1 Ig for 48 h in 10% FCS complete 
RPMI 1640 in round-bottom 96-well plates at 2.5 × 105 cells/
ml. Single cultures were set up in which WT congenic naïve 
CD4+ T cells and Cbl-b−/− naïve CD4+ T cells were stimulated 
separately. Cocultures were set up in which these two naïve 
CD4+ T cell populations were cultured and stimulated together. 
Cells in these cultures were stained with Live/Dead, anti-CD8α 
or anti-CD4, anti-CD45.1, and anti-CD45.2 (Biolegend) and 
analyzed by flow cytometry using Becton Dickinson LSRII for 
CFSE dilution.
liver Metastasis Model of B16 Melanoma 
and anti-PD-1 antibody Treatment
B16 (B16F10) cells were grown to approximately 75% conflu-
ency in 10% FCS complete RPMI 1640 (supplemented with 
l-glutamine, penicillin/streptomycin, non-essential amino 
acids, and sodium pyruvate). 1 ×  106 B16 (B16F10) cells were 
intra-splenically injected into WT and Cbl-b−/− mice. For the 
experiment with anti-PD-1 ab treatment, only WT mice were 
administered 100  μg/mouse of either anti-PD-1 monoclonal 
ab (BioXCell, West Lebanon, NH, USA) or isotype control 
(BioXCell) intraperitoneally on the day of tumor injection and 
every other day. On days 7–9, the mice were perfused with saline, 
and the liver and spleen were harvested from each mouse. The 
images of each spleen and the front and the back side of each 
liver tissue were taken using Panasonic Lumix DMC-FS7 camera 
(Panasonic, Osaka, Japan). Using these images, the percentages of 
tumor foci area in total liver area were quantified for each mouse 
using ImageJ software (National Institutes of Health).
statistical analysis
Data were analyzed by unpaired two-tailed Student’s t-test or 
one-way ANOVA using GraphPad Prism Version 6.0 (GraphPad 
Software, La Jolla CA, USA). Statistical significance was accepted 
at p < 0.05.
resUlTs
cbl-b−/− T cells are resistant to PD-l1 
ig-Mediated suppression of Proliferation
It has previously been demonstrated that in vitro T cell prolifera-
tion and cytokine production can be suppressed by the immo-
bilized recombinant PD-L1 Ig (16, 24–26). To begin to test the 
sensitivity of Cbl-b−/− T cells to PD-L1-mediated suppression, we 
tested the ability of plate-bound PD-L1 Ig to suppress the in vitro 
proliferation of WT and Cbl-b−/− CD8+ T cells. Mouse splenic 
naïve CD44low CD8+ T cells were purified from WT and Cbl-
b−/− mice and labeled with CFSE. These populations were then 
stimulated in  vitro with plate-bound anti-CD3 ab and soluble 
anti-CD28 ab in the presence of either plate-bound PD-L1 Ig or 
plate-bound control human IgG1 (control Ig). After 3 days, cells 
were assayed for dilution of CFSE by flow cytometry. We found 
that TCR-stimulated in vitro proliferative responses of naïve WT 
CD8+ T cells were significantly suppressed by PD-L1 Ig (mean 
% CFSE-diluted cells: control Ig: 63.7%; PD-L1 Ig: 15.03%; 
p = 0.0234) (Figures 1A,B). In contrast, the proliferation of naïve 
Cbl-b−/− CD8+ T cells was not suppressed by PD-L1 Ig (mean 
% CFSE-diluted cells: control Ig: 85.2%, mean PD-L1 Ig: 82.5%; 
p = 0.204) (Figures 1A,B). Thus, the mean percent suppression of 
CFSE-diluted WT CD8+ T cells by PD-L1 Ig was 79.6%, and that 
of CFSE-diluted Cbl-b−/− CD8+ T cells was 3.13% (p = 0.0057) 
(Figure  1B). These differences in percent PD-L1 Ig-mediated 
suppression of CD8+ T cells were also reflected in absolute num-
bers of CFSE-diluted cells (data not shown).
To determine if the difference in PD-L1 Ig-mediated suppres-
sion was associated with differences in cell death, we compared 
the number of dead cells present in the control Ig wells with the 
number of dead cells in the PD-L1 Ig wells at the termination of 
the cultures. We found that PD-L1 Ig-mediated suppression of 
WT CD8+ T cells was associated with an increase in dead cells 
by 46%. In contrast, PD-L1 Ig-mediated suppression of Cbl-
b−/− CD8+ T cells was associated with an increase in dead cells 
by 13.7% (Figure 1C). Overall, our results suggest a resistance 
of Cbl-b−/− CD8+ T cells to PD-L1 Ig-mediated suppression of 
proliferation.
FigUre 1 | cbl-b−/− cD8+ T cells are resistant to PD-l1 fusion protein 
(PD-l1 ig)-mediated suppression of proliferation. Purified splenic naive 
Cbl-b−/− and WT CD8+ T cells were CFSE-labeled and stimulated for 3 days 
with plate-bound anti-CD3 ab and soluble anti-CD28 ab in the presence of 
either plate-bound control Ig or PD-L1 Ig. After 3 days, the percentage of 
CFSE-diluted cells was assayed by flow cytometry. (a) Representative FACS 
plots showing the percentages of CFSE-diluted cells in cultures of CD8+ T 
cells stimulated in the presence of control Ig or PD-L1 Ig (gated on live single 
CD8+ cells). Unstimulated cells are shown in gray. (B) Percentages of 
CFSE-diluted cells in cultures of CD8+ T cells stimulated in the presence of 
control Ig or PD-L1 Ig. (c) Number of dead cells in cultures of CD8+ T cells 
stimulated in the presence of control Ig or PD-L1 Ig. n = 3; Mean ± SEM 
depicted. Student’s t-test: *p < 0.05.
FigUre 2 | cbl-b−/− cD4+ T cells are resistant to PD-l1 fusion protein 
(PD-l1 ig)-mediated suppression of proliferation. Purified splenic naïve 
Cbl-b−/− and WT CD4+ T cells were CFSE-labeled and stimulated for 2 days 
with plate-bound anti-CD3 ab and soluble anti-CD28 ab in the presence of 
either plate-bound control Ig or PD-L1 Ig. After 2 days, the percentage of 
CFSE-diluted cells was assayed by flow cytometry. (a) Representative FACS 
plots showing the percentages of CFSE-diluted cells in cultures of CD4+ T 
cells stimulated in the presence of control Ig or PD-L1 Ig (gated on live single 
CD4+ cells). Unstimulated cells are shown in gray. (B) Percentages of 
CFSE-diluted cells in cultures of CD4+ T cells stimulated in the presence of 
control Ig or PD-L1 Ig. (c) Numbers of dead cells in cultures of CD4+ T cells 
stimulated in the presence of control Ig or PD-L1 Ig. n = 3; Mean ± SEM 
depicted. Student’s t-test: *p < 0.05, ***p < 0.001.
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Next, we asked whether Cbl-b−/− CD4+ T cells were also 
resistant to PD-L1 Ig-mediated suppression of in vitro prolifera-
tion. Mouse splenic naïve CD44low CD4+ T cells isolated from 
WT and Cbl-b−/− mice were labeled with CFSE and subjected 
to the similar stimulation cultures described above for CD8+ 
T cells. After 2 days, cells were assayed for dilution of CFSE by 
flow cytometry. Similar to CD8+ T cells, the in vitro proliferative 
responses of WT CD4+ T cells were significantly inhibited by 
PD-L1 Ig (mean % CFSE-diluted cells: control Ig: 68.4%; PD-L1 
Ig: 14.1%; p = 0.0005) (Figures 2A,B). In contrast, the prolif-
erative responses of Cbl-b−/− CD4+ T cells were significantly 
less suppressed in the presence of PD-L1 Ig (mean % CFSE-
diluted cells: control Ig: 82.0%; PD-L1 Ig: 66.9%; p =  0.0114) 
(Figures 2A,B). While a small and statistically significant degree 
of PD-L1 Ig-mediated suppression was noted in Cbl-b−/− CD4+ 
T cells (mean percent suppression of Cbl-b−/− CD4+ T cells: 
18.4%), this level of suppression was markedly less than that 
seen in WT CD4+ T cells (mean percent suppression: 79.8%) 
(Figure  2B). These differences in percent PD-L1 Ig-mediated 
suppression of CD4+ T cells were also reflected in absolute 
numbers of CFSE-diluted cells (data not shown).
To determine if differences in PD-L1-mediated suppression 
between naïve WT versus Cbl-b−/− CD4+ cells were associated 
with differences in cell death, we compared the number of dead 
cells present in the control Ig wells with the number of dead cells 
in PD-L1 Ig wells at the termination of cultures. We found that 
PD-L1-mediated suppression of WT CD4+ T cells was associ-
ated with an increase in dead cells by 30%. In contrast, PD-L1-
mediated suppression of Cbl-b−/− CD4+ T cells was not associated 
with a significant change in the number of dead cells (Figure 2C). 
FigUre 3 | The expression of PD-1 is not decreased in cbl-b−/− cD8+ 
and cD4+ T cells. For ex vivo studies, splenocytes were derived from 
Cbl-b−/− and WT mice and labeled with anti-CD8, anti-CD4, anti-PD-1, and 
anti-CD44 abs, immediately ex vivo. Alternatively, purified CD4+ and CD8+ T 
cells were labeled with anti-PD-1 ab after 2–3 days in culture with plate-
bound anti-CD3 ab and soluble anti-CD28 ab. These cells were subsequently 
assayed by flow cytometry. (a) Frequencies of total CD8+, or CD8+ CD44low, 
or CD8+ CD44high T cells that were PD-1+ in unstimulated splenocytes (gated 
on live, single, CD8+, CD44low, or CD44hi cells). (B) MFI of PD-1 expression in 
in vitro stimulated CD8+ T cells (gated on live, single, CD8+ cells). (c) 
Frequencies of total CD4+, or CD4+ CD44low, or CD4+ CD44high T cells that 
were PD-1+ in unstimulated splenocytes (gated on live, single, CD4+, CD44low, 
or CD44hi cells). (D) MFI of PD-1 expression in in vitro stimulated CD4+ T cells 
(gated on live, single, CD4+ cells). n = 3; Mean ± SEM depicted. Student’s 
t-test: *p < 0.05, **p < 0.01.
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Overall, as with Cbl-b−/− CD8+ T cells, our results suggest a resist-
ance of Cbl-b−/− CD4+ T cells to PD-L1 Ig-mediated suppression 
of proliferation.
The expression of PD-1 is not Decreased 
in cbl-b−/− cD8+ and cD4+ T cells
To determine whether the resistance of Cbl-b−/− T cells to PD-L1 
Ig-mediated suppression is a result of decreased PD-1 expression, 
we compared the expression of PD-1 in WT versus Cbl-b−/− CD8+ 
and CD4+ T cells before and after in vitro TCR stimulation. In 
CD8+ T cells, the frequency of PD-1+ cells was comparable between 
unstimulated WT and Cbl-b−/− CD8+ T cells, and this was true 
for total CD8+ T cells, CD44low, and CD44high CD8+ populations 
(Figure 3A). After 3 days of in vitro stimulation, approximately 
95% of CD8+ T cells were positive for PD-1 expression. Therefore, 
we examined the MFI of PD-1 expression in these activated cells 
and found that the PD-1 MFI was comparable between Cbl-b−/− 
and WT CD8+ T cells (Figure 3B). Unstimulated Cbl-b−/− CD4+ 
T cells, when compared to unstimulated WT CD4+ T cells, dem-
onstrated an increased frequency of PD-1+ cells. This was true 
for total CD4+ T cells, CD44low and CD44high CD4+ populations 
(Figure 3C). After 2 days of in vitro stimulation, the PD-1 MFI 
was significantly higher in Cbl-b−/− CD4+ T cells compared to 
WT cells (Figure 3D). These results suggest that the resistance of 
Cbl-b−/− T cells to PD-L1 Ig-mediated suppression is not a result 
of decreased PD-1 expression.
PD-l1 ig-Mediated suppression of iFn-γ 
is significantly greater for WT than for 
cbl-b−/− T cells
We next asked whether Cbl-b−/− T cells were resistant not only to 
PD-L1 Ig-mediated suppression of proliferation but also resist-
ant to suppression of IFN-γ production in vitro. Splenic naïve 
CD44low CD8+ T cells isolated from WT and Cbl-b−/− mice were 
stimulated with anti-CD3 and anti-CD28 abs in the presence of 
plate-bound PD-L1 Ig or control Ig. After 3 days of culture, these 
cells were stained for intracellular IFN-γ, and analyzed by flow 
cytometry.
The frequency of IFN-γ-producing WT CD8+ T cells was 
significantly suppressed by PD-L1 Ig (mean IFN-γ positive cells: 
control Ig: 12.8%; PD-L1 Ig: 0.3%; p = 0.0221) (Figures 4A,B). 
In contrast, the frequency of IFN-γ-producing Cbl-b−/− CD8+ 
T cells was not statistically suppressed by PD-L1 Ig (mean 
IFN-γ positive cells: control Ig: 18.1%, mean PD-L1 Ig: 14.8%; 
p = 0.1374) (Figures 4A,B). Thus, the level of suppression was 
significantly lower in Cbl-b−/− CD8+ T cells than that seen in WT 
CD8+ T cells (mean percent suppression of IFN-γ-producing 
cells: WT CD8+: 96.3%; Cbl-b−/− CD8+: 18.1%; p  =  0.0001) 
(Figure 4C).
We next stimulated WT and Cbl-b−/− splenic naïve CD44low 
CD4+ T cells with anti-CD3 and anti-CD28 abs in the pres-
ence of plate-bound PD-L1 Ig or control Ig. As with WT CD8+ 
T cells, the frequency of IFN-γ-producing WT CD4+ T cells was 
significantly suppressed by PD-L1 Ig (mean IFN-γ positive cells: 
control Ig: 7.7%; PD-L1 Ig: 2.4%; p = 0.0177) (Figures 4D,E). 
The frequency of IFN-γ-producing Cbl-b−/− CD4+ T cells was 
also suppressed by PD-L1 Ig (mean IFN-γ positive cells: control 
Ig: 28.4%; PD-L1 Ig: 22.6%; p = 0.0146) (Figures 4D,E), but the 
level of suppression was significantly less than that seen with WT 
CD4+ T cells (mean percent suppression of IFN-γ-producing 
cells: WT CD4+: 68.3%; Cbl-b−/− CD4+: 20.1%; p  <  0.0001) 
(Figure 4F). Thus, consistent with the proliferation results, Cbl-
b−/− CD8+ and CD4+ T cell IFN-γ production is significantly less 
suppressed by PD-L1 Ig than is WT CD8+ and CD4+ T cell IFN-γ 
production.
cbl-b−/− nK cells are resistant to PD-l1-
Mediated suppression of iFn-γ Production
The role of NK cells has been documented in antitumor immu-
nity in mice and humans, and these cells have been shown to 
contribute to the robust antitumor immunity of Cbl-b−/− mice 
(14). Similar to T cells, NK cells can also express PD-1 and the 
engagement of PD-1 on NK cells inhibits their activation and 
FigUre 4 | PD-l1 fusion protein (PD-l1 ig)-mediated suppression of iFn-γ is significantly greater for WT than for cbl-b−/− T cells. Purified naïve splenic 
Cbl-b−/− and WT CD8+ CD44low and CD4+ CD44low T cells were stimulated for 3 days with plate-bound anti-CD3 ab and soluble anti-CD28 ab in the presence of 
either plate-bound control Ig or PD-L1 Ig. For both CD8+ and CD4+ T cell cultures, brefeldin A was added in the last 4 h of culture, and cells were intracellularly 
stained with anti-IFN-γ ab and analyzed by flow cytometry. (a) Representative FACS plots showing the percentages of IFN-γ+ cells in cultures of CD8+ T cells 
stimulated in the presence of control Ig or PD-L1 Ig (gated on live single CD8+ cells). (B) Mean frequencies of IFN-γ-producing CD8+ T cells stimulated in the 
presence of either control Ig or PD-L1 Ig. (c) Mean percentage suppression of CD8+ T cell IFN-γ production by PD-L1 Ig as shown in panel (B). (D) Representative 
FACS plots showing the percentages of IFN-γ+ cells in cultures of CD4+ T cells stimulated in the presence of control Ig or PD-L1 Ig (gated on live single CD4+ cells). 
(e) Mean frequencies of IFN-γ-producing CD4+ T cells stimulated in the presence of control Ig or PD-L1 Ig. (F) Mean percentage suppression of CD4+ T cell IFN-γ 
production by PD-L1 Ig as shown in panel (e). Mean ± SEM depicted. n = 3 for panels (B) and (c); n = 5–6 for panels (e) and (F). Student’s t-test: *p < 0.05, 
***p < 0.001, ****p < 0.0001.
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cytotoxic function (27). We, next, asked whether Cbl-b−/− NK 
cells were also resistant to PD-L1/PD-1 suppression.
WT and Cbl-b−/− splenic NK cells were isolated and initially 
cultured in the presence of IL-2 as previously described (28). The 
mean purity or percentages of NK cells after 7  days of culture 
with IL-2 was WT = 97.57% and Cbl-b−/− = 96.3% when gated 
on CD3− NK1.1+ cells. After 7  days of culture, WT NK cells 
contained an average of 1.7% CD3+ T cells, and Cbl-b−/− NK cells 
contained an average of 0.5% CD3+ T cells (data not shown). 
The NK cells were then stimulated in  vitro with plate-bound 
anti-NK1.1 ab in the presence of either plate-bound PD-L1 Ig 
or control Ig and IFN-γ production measured by intracellular 
staining and flow cytometry. Additionally, the expression of PD-1 
on the unstimulated NK cells was examined by flow cytometry. 
The frequency of IFN-γ-producing WT NK cells after stimulation 
with plate-bound anti-NK1.1 ab was significantly suppressed by 
PD-L1 Ig (p = 0.0022) (Figures 5A,B). In contrast, the frequency 
of IFN-γ-producing Cbl-b−/− NK cells was not suppressed by 
PD-L1 Ig (Figures 5A,B). Overall, the mean percentage of PD-L1 
Ig-mediated suppression of IFN-γ-producing WT NK cells was 
11.5%, while the mean percent suppression of IFN-γ-producing 
Cbl-b−/− NK cells was −3.4% (p = 0.0006) (Figure 5C). Although 
it did not reach statistical significance, PD-L1 Ig reduced the 
IFN-γ expression of WT NK cells based on the MFI, while that 
of Cbl-b−/− NK cells was not reduced by PD-L1 Ig (Figure 5D). 
Finally, PD-1 expression by Cbl-b−/− NK cells was slightly, but 
not statistically, lower than PD-1 expression on WT NK cells 
(p = 0.304) (Figure 5E). These results suggest that, in addition 
to Cbl-b−/− T cells, Cbl-b−/− NK cells are also significantly less 
sensitive to suppression by PD-L1 Ig.
Does coculturing with cbl-b−/− T cells 
result in Bystander WT T cell resistance 
to PD-l1-Mediated suppression?
To begin to investigate the potential functional relevance of 
Cbl-b−/−’s resistance to PD-L1 suppression, we focused on 
reports documenting that enhanced levels of certain common 
FigUre 5 | cbl-b−/− nK cells are resistant to PD-l1 fusion protein (PD-l1 ig)-mediated suppression of iFn-γ production. Splenic NK cells were isolated 
from Cbl-b−/− and WT mice and cultured for 7 days in the presence of IL-2. These NK cells were harvested from the 7-day cultures and stimulated with plate-bound 
anti-NK1.1 ab in the presence of either plate-bound control Ig or plate-bound PD-L1 Ig and brefeldin A for 5 h. The NK cells were then intracellularly stained with 
anti-IFN-γ ab and analyzed by flow cytometry. Additionally, unstimulated NK cells were stained with anti-PD-1 ab after the 7-day IL-2 culture and analyzed by flow 
cytometry. (a) Representative dot blots and corresponding histograms on 7-day-cultured NK cells stained for intracellular IFN-γ. Cells were gated on live single WT or 
Cbl-b−/− CD3− (dot blots) or CD3− CD49b+ cells (histograms) that had been stimulated in the presence of control Ig or PD-L1 Ig. In histograms: black line represents 
isotype staining, red line represents control Ig, and blue line represents PD-L1 Ig. (B) Mean frequencies of IFN-γ-producing WT or Cbl-b−/− NK cells stimulated in the 
presence of control Ig or PD-L1 Ig (gated on live single CD3− CD49b+ cells). (c) Mean percentage suppression of IFN-γ-producing NK cells after stimulation in the 
presence of PD-L1 Ig as shown in panel (a). (D) Mean MFI of IFN-γ staining in 7-day cultured WT or Cbl-b−/− NK cells stimulated in the presence of control Ig or 
PD-L1 Ig (gated on live single CD3− CD49b+ cells). (e) Mean MFI by flow cytometry of PD-1 expression in unstimulated WT and Cbl-b−/− NK cells that were harvested 
from the 7-day IL-2 culture (gated on live single CD3− NK1.1+ CD49b+ cells). Mean ± SEM depicted. n = 3. Student’s t-test: **p < 0.01, ***p < 0.001.
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γ chain-signaling cytokines may have a role in overcoming 
PD-L1-mediated suppression (29). It has been documented that 
activated  Cbl-b−/− T cells secrete increased levels of IL-2 com-
pared to WT T cells (1, 2). Therefore, we next explored whether 
this might result in the induction of bystander PD-L1 resistance 
in WT T cells. We cultured naïve Cbl-b−/− T cells or naïve WT T 
cells either separately or together and then asked whether factors 
secreted by activated Cbl-b−/− T cells would induce PD-L1 resist-
ance in bystander (cocultured) WT T cells.
In the CD8+ T cell cultures, there was a clear, though not 
statistically significant (p = 0.08) effect of naive Cbl-b−/− CD8+ 
T cells in diminishing the PD-L1 Ig-mediated suppression of 
bystander naïve WT CD8+ T cells (Figure 6A). The mean PD-L1 
Ig-mediated suppression of WT CD8+ T cells in single culture 
was 79.6%, and this suppression decreased to a mean of 42.9% 
when WT CD8+ T cells were cocultured with Cbl-b−/− CD8+ 
T cells (Figure  6A). These results suggest that Cbl-b−/− CD8+ 
T cells can induce a partial resistance of bystander WT CD8+ 
T cells to PD-L1 Ig-mediated suppression. In contrast, the 
level of PD-L1 Ig-mediated suppression of WT CD4+ T cells 
remained unchanged, regardless of whether WT CD4+ T cells 
were cultured alone or cocultured together with Cbl-b−/− CD4+ 
T cells (Figure 6B). In terms of potential functional relevance, 
these results suggest that the adoptive transfer of CD8+ T cells in 
which the expression of the CBLB gene has been silenced may be 
accompanied by a loss of sensitivity to PD-L1-mediated suppres-
sion among bystander endogenous T cells.
cbl-b−/− Mice Develop significantly Fewer 
Metastases in a PD-l1/PD-1-Dependent 
Model of B16 Melanoma liver Metastasis
As Cbl-b−/− T cells were resistant to PD-L1 Ig-mediated regula-
tion in vitro, we sought to test this in an in vivo B16 melanoma 
FigUre 6 | PD-l1 fusion protein (PD-l1 ig)-suppression in cocultures 
of cbl-b−/− and WT T cells. Naïve CD8+ CD44low T cells and naïve CD4+ 
CD44low T cells were isolated from spleens of WT C57BL/6, CD45.1+ 
congenic mice, and Cbl-b−/− mice (CD45.2+). WT and Cbl-b−/− T cells were 
CFSE-labeled and stimulated for 3 (CD8+) or 2 (CD4+) days either separately 
(WT and Cbl-b−/− T cells in separate cultures) or together (“Co” = WT and 
Cbl-b−/− T cells cultured together) with plate-bound anti-CD3 ab and soluble 
anti-CD28 ab in the presence of either plate-bound control Ig or PD-L1 Ig. At 
the end of culture, the percentage of CFSE-diluted cells was assayed by flow 
cytometry. (a) Mean percentage suppression by PD-L1 Ig of single and 
cocultures of naïve CD8+ CD44low T cells stimulated in the presence of control 
Ig or PD-L1 Ig. Co-WT indicates % suppression of WT CD8+ T cells by 
PD-L1 in the coculture of WT and Cbl-b−/− CD8+ T cells. Co-Cbl-b−/− 
indicates % suppression of Cbl-b−/− CD8+ T cells by PD-L1 Ig in the same 
coculture. (B) Mean percentage suppression by PD-L1 Ig of single and 
cocultures of naïve CD4+ CD44low T cells stimulated in the presence of control 
Ig or PD-L1 Ig. Co-WT indicates % suppression of WT CD4+ T cells by 
PD-L1 in the coculture of WT and Cbl-b−/− CD4+ T cells. Co-Cbl-b−/− 
indicates % suppression of Cbl-b−/− CD4+ T cells by PD-L1 Ig in the same 
coculture. n = 3; Mean ± SEM depicted. One-way ANOVA: **p < 0.01, 
****p < 0.0001.
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tumor model in which inhibiting the PD-L1/PD-1 pathway has 
been shown to prevent the outgrowth of liver metastases (30). 
In this model, splenic injection of B16 melanoma in WT mice 
results in significant metastatic foci in the liver. However, if anti-
PD-1 antibody is administered, liver metastases are significantly 
reduced (30). In addition, Iwai et  al. documented that PD-1−/− 
mice develop significantly fewer liver metastases compared to WT 
mice in this model (30). Thus, PD-L1/PD-1-mediated immune 
regulation appears to normally allow spread of the melanoma to 
the liver, while inhibiting or deleting this normal PD-1/PD-L1-
mediated immune regulation prevents the spread of the tumor 
to the liver. This model allows us to ask whether Cbl-b−/− mice 
can eliminate the B16 liver metastases on their own, i.e., in the 
absence of anti-PD-1 antibody, and thus to assess the functional 
relevance of the in vitro resistance of Cbl-b−/− T cells to PD-L1/
PD-1 in an in vivo tumor setting.
In using this model, Cbl-b−/− mice could potentially eliminate 
liver metastases on the basis of their resistance to TGF-β or Tregs 
(7–11). However, if Cbl-b−/− mice were unable to eliminate the 
liver metastases in the absence of anti-PD-1 antibody, this would 
suggest that Cbl-b−/− mice are not resistant to PD-L1/PD-1 sup-
pression in vivo. In contrast, demonstrating that Cbl-b−/− mice can 
indeed eliminate the liver metastases in the absence of anti-PD-1 
antibody would minimally suggest a lack of dominant sensitivity 
to PD-L1/PD-1 suppression in vivo and thus be consistent with 
our in vitro findings.
We first confirmed using WT mice that the model was sensi-
tive to anti-PD-1 antibody treatment. WT mice were injected 
intra-splenically with B16 melanoma and treated with either anti-
PD-1 ab or an isotype control. As reported by Iwai et al (30), WT 
mice treated with anti-PD-1 ab developed significantly fewer liver 
metastases than mice treated with isotype control (Figures 7A,C). 
No difference in the “primary” spleen tumor masses was noted 
between mice treated with anti-PD-1 ab or isotype (data not 
shown). Next, WT and Cbl-b−/− mice were injected intra-spleni-
cally with B16 melanoma and the presence of liver metastases was 
analyzed 7–9 days after the tumor injection. No anti-PD-1 ab or 
isotype treatment was given to these mice. Strikingly, we found 
that Cbl-b−/− mice developed significantly fewer liver metastases 
compared to WT mice (Figures 7B,D). In contrast, the primary 
spleen tumor masses were comparable between WT and Cbl-
b−/− mice in all of the experiments (Figure 7D), suggesting that 
Cbl-b−/− mice are not generally capable of eliminating the B16 
melanoma based on their resistance to TGF-β or Tregs (7–11). 
Our finding that Cbl-b−/− mice develop significantly fewer liver 
metastases compared to WT mice without the administration of 
anti-PD-1 antibody minimally suggests a lack of dominant sen-
sitivity to PD-L1/PD-1 suppression in vivo and thus is consistent 
with our in vitro findings of resistance to PD-L1/PD-1-mediated 
suppression.
DiscUssiOn
Casitas B-lineage lymphoma-b is an E3 ubiquitin ligase that nega-
tively regulates T cell activation (1–4). Cbl-b−/− mice demonstrate 
spontaneous autoimmunity and robust antitumor immunity.
Recently, enhancement of antifungal immunity has also been 
documented in Cbl-b−/− mice (31–33). The enhanced antitumor 
responses of Cbl-b−/− mice have been documented in tumor 
models of EL4 (11), EG.7 (10), TC-1 (4, 9), UVB-induced skin 
tumor (9), and ATM-deficiency-induced T cell lymphoma (10). 
The T cell-intrinsic role of the enhanced antitumor immunity of 
Cbl-b−/− mice has been demonstrated in adoptive T cell transfer 
experiments using Cbl-b−/− or Cblb-silenced CD8+ T cells (9, 10, 
34–36). In an attempt to elucidate the mechanisms underlying 
the robust antitumor activity of Cbl-b−/− T cells, we and others 
FigUre 7 | cbl-b−/− mice develop significantly fewer liver metastases in a PD-l1/PD-1-dependent model of B16 melanoma liver metastasis.  
(a) WT mice received an intra-splenic injection of B16 melanoma cells and then were treated with either 100 µg of isotype control ab or anti-PD-1 ab i.p. on the day 
of tumor injection and every other day until the mice were sacrificed. The mice were sacrificed on day 8, perfused with saline, the liver and the spleen harvested, and 
the percentages of tumor foci area/total liver area were quantified using ImageJ software. (B) WT and Cbl-b−/− mice received an intra-splenic injection of B16 
melanoma cells as in panel (a), but no isotype or anti-PD-1 ab was given. The mice were sacrificed on day 7–9, perfused with saline, the liver and the spleen 
harvested, and the percentages of tumor foci area/total liver area were quantified using ImageJ software. (c) Images of the livers from the experiment shown in 
panel (a). (D) Representative images of liver and spleen from panel (B) with percentages of tumor foci area/total liver area for the livers presented. Mean ± SEM 
depicted. n = 3 for panel (a), n = 12–14 for panel (B). Student’s t-test: *p = 0.019 for panel (a); *p = 0.026 for panel (B).
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have shown that Cbl-b−/− T cells are resistant to suppression by 
Tregs (7–9) and TGF-β (10, 11). Because of the enhanced anti-
tumor responses of Cbl-b−/− mice, Cbl-b has become a focus for 
understanding mechanisms of antitumor immunity and a target 
for manipulation in antitumor immunotherapeutic approaches. 
In this regard, siRNA-mediated knockdown of CBLB is cur-
rently being investigated as a therapeutic approach to enhance 
antitumor responses in cancer patients (34, 36, 37). Similar to 
the findings in mouse Cbl-b−/− CD8+ T cells, CBLB-silenced 
human CD8+ T cells demonstrate enhanced IFN-γ production 
(34, 36), reduced sensitivity to TGF-β (36), and independence 
from co-stimulation (36) and exogenous IL-2 in activation and 
proliferation (34). These findings in human CBLB-silenced T cells 
suggest their potential for mediating robust antitumor activity 
in vivo and underlie the high level of interest in utilizing CBLB 
silencing in treating human cancer patients.
PD-1 belongs to the CD28/B7 family of co-stimulatory mol-
ecules and is expressed on activated CD8+ and CD4+ T cells, NK 
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and NKT cells, B cells, activated monocytes, and some dendritic 
cells (38). Triggering of PD-1 in T cells by its ligands PD-L1 and 
PD-L2 has been shown to inhibit activation and dampen sub-
sequent proliferation and cytokine production (15, 16, 24–26). 
The expression of PD-L1 on tumors has been shown to increase 
the invasiveness of the tumor in mice and blockade of PD-L1/
PD-1 interaction has been shown to halt tumor progression in 
mouse models (30, 39). Furthermore, the recent demonstration 
of the efficacy of the PD-L1/PD-1 blockade for the treatment of 
certain human cancers underscores the importance of inhibiting 
this pathway for effective antitumor immunity (17–19). Despite 
the documented ability of Cbl-b−/− mice to mount enhanced 
antitumor responses, to date, there has been no investigation 
of the relationship of Cbl-b deficiency and the PD-L1/PD-1 
pathway. In the present study, we now report a relationship with 
potential translational significance between Cbl-b deficiency 
and a resistance to PD-L1/PD-1-mediated immune regulation. 
This concept is supported by the following specific results in 
our study.
We find that in vitro proliferative responses of Cbl-b−/− CD8+ 
and CD4+ T cells are significantly less suppressed by a recombi-
nant PD-L1 Ig than are those of WT T cells.
In addition to the proliferative responses, in  vitro IFN-γ 
production of Cbl-b−/− CD8+ and CD4+ T cells is also sig-
nificantly less suppressed by PD-L1 Ig compared to WT T cells. 
The PD-1/PD-L1 resistance of Cbl-b−/− T cells is not a result 
of a difference in PD-1 expression in Cbl-b−/− CD8+ and CD4+ 
T cells. Recently, Cbl-b−/− mice have been reported to have NK 
cells with enhanced antitumor activity (14). This enhancement 
of antitumor activity in Cb-b−/− NK cells was reported to be 
associated with their resistance to TAM (Tyro3, Axl, and Mer) 
receptor-mediated inhibition (14). Similar to T cells, NK cells 
can express PD-1, and the engagement of PD-1 on NK cells 
inhibits their activation and cytotoxic function (27). We asked 
whether the enhanced antitumor activity of Cbl-b−/− NK cells 
might also be related to a resistance to PD-L1/PD-1-mediated 
suppression. We now find that in contrast to WT NK cells, Cbl-
b−/− NK cells are not suppressed in in vitro IFN-γ production by 
PD-L1. Thus, we have described an additional mechanism by 
which Cbl-b−/− NK cells may be capable of mediating enhanced 
antitumor activity.
To begin to identify the potential functional relevance of 
resistance to PD-L1 Ig-mediated suppression in Cbl-b−/− T cells, 
we asked whether Cbl-b−/− T cells could induce resistance to 
PD-L1-mediated suppression in bystander WT T cells. Although 
not statistically significant, we find an induction of bystander 
resistance in naïve WT CD8+ T cells when cultured with naïve 
Cbl-b−/− CD8+ T cells. There is presently a significant focus 
on developing approaches to silence CBLB in CD8+ T cells for 
subsequent use in enhancing antitumor immunity (34, 36, 40). 
Our coculture results suggest that the adoptive transfer of CD8+ 
T cells in which CBLB has been silenced may result in a sig-
nificant enhancement of T cell antitumor responses through both 
PD-L1 resistance in the CBLB-silenced T cells and induction of 
bystander PD-L1 resistance in the endogenous T cell populations.
Finally, we examined the in vivo relevance of the resistance of 
Cbl-b−/− T cells to PD-L1/PD-1 utilizing a previously established 
tumor model in which the spread of intra-splenically injected 
B16 melanoma requires functionally intact PD-L1/PD-1 regula-
tion (30). The ideal system for testing the PD-1/Cbl-b interaction 
in vivo would require a model in which PD-L1/PD-1 suppres-
sion can be analyzed without other confounding suppressive 
influences. Current models only allow us to interrogate systems 
in which PD-L1/PD-1 has been shown to play a crucial role, 
while not directly ruling out the influence of other pathways. 
As such, we chose a model system in which blockade of PD-1 is 
known to be effective in eradicating liver metastases.
Strikingly, we found that, in the absence of anti-PD-1 treat-
ment, Cbl-b−/− mice develop far fewer metastatic tumor foci in 
the liver compared to WT mice. It should be noted that simul-
taneously, we found that the “primary” spleen tumor masses 
were comparable between WT and Cbl-b−/− mice. This suggests 
that Cbl-b−/− mice are not broadly capable of eliminating the 
B16 melanoma in all clinical settings, for example as a result 
of their resistance to TGF-β or Tregs (7–11). Moreover, this 
apparent lack of relevance of PD-L1/PD-1 regulation in splenic 
tumor outgrowth is consistent with the finding of Iwai et  al., 
who reported that when B16 melanoma is administered sub-
cutaneously, PD-1−/− mice demonstrate tumor growth which is 
comparable to that seen in WT mice (30, 39). In sum, our finding 
that Cbl-b−/− mice develop significantly fewer liver metastases 
compared to WT mice suggests, minimally, a lack of dominant 
sensitivity of Cbl-b−/− mice to PD-L1/PD-1 suppression in vivo 
and thus is consistent with our in vitro findings of resistance to 
PD-L1/PD-1-mediated suppression.
There are several potential mechanisms by which Cbl-b−/− 
T cells may resist suppression by PD-L1/PD-1. Karwacz et al. 
have previously reported that PD-1/PD-L1 interaction following 
TCR/CD28 stimulation induces both the upregulation of Cbl-b 
and TCR down-modulation in CD8+ T cells (23). Cbl-b−/− CD8+ 
and CD4+ T cells have previously been shown to be defective in 
TCR down-modulation during T cell priming (41, 42). Based on 
these findings, Karwacz et al. have proposed that during PD-L1/
PD-1 signaling, Cbl-b is required for the TCR down-modulation 
leading to the inhibition of T cell responses (23). However, the 
requirement for Cbl-b in the PD-L1/PD-1-mediated inhibition 
of T cell responses was never directly demonstrated in their 
study through the use of Cbl-b−/− T cells. Moreover, Karwacz 
et  al. did not observe TCR down-modulation in response to 
PD-L1/PD-1 signaling in CD4+ T cells and only focused on 
CD8+ T cells in their study. However, as noted above, it has been 
reported that both Cbl-b−/− CD8+ and CD4+ T cells are defective 
in TCR down-modulation in response to in  vitro stimulation 
(41, 42). This suggests that the resistance to PD-L1-mediated 
suppression we now report for both Cbl-b−/− CD8+ and CD4+ 
T  cells may involve mechanisms other than a resistance to 
PD-L1-induced TCR down-modulation.
Perhaps related to this concept, it has been reported that 
PD-L1/PD-1 signaling may act downstream by interacting 
with inhibitory phosphatases, such as SHP-1 and SHP-2 (22, 
25, 26). In this regard, Xiao et al. recently demonstrated that 
after TCR stimulation, SHP-1 dephosphorylates Cbl-b to 
prevent its degradation (43). Thus, in the context of both TCR 
and PD-1 signaling in T cells, SHP-1 may also act to prevent 
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degradation of Cbl-b, allowing Cbl-b to optimally inhibit its 
targets such as PI3K through its E3 ubiquitin ligase activity. 
PI3K has been described as one of the proximal TCR signaling 
molecules affected by PD-L1/PD-1 inhibitory signals along 
with Zap70 and PKC-θ (20, 21). Furthermore, Xiao et al. also 
documented that CD28 co-stimulatory signals block the inter-
action between SHP-1 and Cbl-b, allowing the degradation of 
Cbl-b. CD28 co-stimulation has previously been described to 
allow both mouse and human T cells to overcome suppression 
by PD-L1/PD-1 (29, 44). The disrupted interaction between 
SHP-1 and Cbl-b may be one of the underlying mechanisms by 
which CD28 co-stimulation diminishes PD-L1/PD-1 inhibi-
tory signals (44).
Finally, Cbl-b−/− T cells demonstrate increased production of 
IL-2 (1, 2). Exogenous IL-2 and certain other γ chain-signaling 
cytokines have been demonstrated to enable mouse and human 
T cells to overcome PD-L1/PD-1 inhibitory signals (29, 44). 
Our coculture studies suggest that enhanced cytokine secre-
tion by Cbl-b−/− CD8+ T cells may induce resistance to PD-L1/
PD-1-mediated suppression in bystander WT CD8+ T cells. This 
also suggests that enhanced cytokine secretion may be playing 
a mechanistic role, in an autocrine fashion, in the PD-L1/PD-1 
resistance in Cbl-b−/− CD8+ T cells. Our results indicate however, 
that both of these characteristics may not be the case for CD4+ 
T cells. At present it is unclear why bystander resistance is noted 
in CD8+ but not in CD4+ cocultures. Future studies in our labora-
tory will explore this dichotomy and further identify the specific 
mechanisms by which Cbl-b plays a role in mediating the PD-L1/
PD-1 inhibitory signals.
In sum, we have documented for the first time that Cbl-b 
deficiency in mice results in functional resistance of T cells 
and NK cells to PD-L1/PD-1-mediated immune regulation. 
Cbl-b−/− mice develop only a mild autoimmune phenotype 
consisting of anti-dsDNA antibodies and variably, some degree 
of multi-organ lymphocyte infiltration. These findings occur 
only after approximately 9  months of age. As in all treatments 
that involve checkpoint inhibition in human cancer therapy, the 
use of T cells in which Cbl-b is inactivated will require a close 
watch for the development of autoimmune diseases Nevertheless, 
our results suggest that targeting Cbl-b in cancer immunotherapy 
offers the opportunity to simultaneously override numerous 
relevant “checkpoints” including sensitivity to regulatory T cells, 
suppression by TGF-β, and immune regulation not only by 
CTLA-4 (because of the CD28-independence of Cbl-b−/− T cells) 
but also, as we now report, immune regulation by the PD-L1/
PD-1 pathway.
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